Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects. The fibrin-specific plasminogen activator – which ...
Against all the odds, Roche's Genentech unit has won FDA approval for its clot-busting drug TNKase as a treatment for acute ischaemic stroke, after all but abandoning the project a couple of years ago ...
Our Charitable Giving offering features two types of DAF accounts—referred to as “giving accounts”— that support both your company’s philanthropic objectives as well as individual employee giving.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results